The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1463
March 2, 2015
View Complete Issue         Table of Contents 2019 
Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic
March 2, 2015 (Issue: 1463)
The FDA has approved ceftolozane/tazobactam (Zerbaxa – Cubist), a combination of a new cephalosporin antibiotic and a beta-lactamase inhibitor, for intravenous treatment of complicated urinary tract and intra-abdominal infections in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ceftolozane/Tazobactam (Zerbaxa) - A New Intravenous Antibiotic
Article code: 1463b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.